Palatin Technologies (PTN)
(Delayed Data from AMEX)
$0.96 USD
-0.06 (-5.80%)
Updated Sep 25, 2024 04:00 PM ET
After-Market: $0.94 -0.02 (-2.16%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Palatin Technologies, Inc. [PTN]
Reports for Purchase
Showing records 81 - 100 ( 202 total )
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Bremelanotide Deal Fuels Pipeline Development; Buy, $1.50 PT
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Positive Negotiations With China, as Bremelanotide Rights Are Sold
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Per Management Meeting, Attention Turns Towards Pipeline
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
With Cash in Hand, Palatin Outlines Pipeline?s Agenda; Buy, $1.50 PT
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Reinvigorating Female Sexual Dysfunction With Rekynda; Resuming w/ Buy
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
We are transferring coverage of PTN to Michael Higgins and placing shares Under Review
Provider: Roth Capital Partners, Inc.
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
F1Q17 Results; All Eyes on What''s Next; Our Eyes Say It''s Good
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
A Rousing BMT Clinical Success; Buh Bye Addyi; Target to $7
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
FY16 Results; What''s A Few Weeks? Nothing, as PTN and FDA Align
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Don''t Let the Opportunity Slip By; Big Data Coming Soon
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.